Key terms

About RGNX

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest RGNX news

Mar 11 10:10pm ET Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), OrthoPediatrics (KIDS) and RegenXBio (RGNX) Mar 11 9:34am ET Regenxbio initiated with a Buy at H.C. Wainwright Mar 08 7:15am ET RBC Capital upgrades Regenxbio to Outperform, sees positive risk-reward Mar 08 5:18am ET Regenxbio upgraded to Outperform from Sector Perform at RBC Capital Mar 07 7:12am ET Analysts Are Bullish on These Healthcare Stocks: RegenXBio (RGNX), Biomea Fusion (BMEA) Mar 07 7:01am ET Regenxbio price target raised to $55 from $45 at Barclays Mar 07 6:08am ET Regenxbio 4.57M share Spot Secondary priced at $23.00 Mar 06 4:11pm ET Regenxbio announces $125M common stock offering Mar 06 9:50am ET Nvidia initiated, Target upgraded: Wall Street’s top analyst calls Mar 06 8:09am ET Leerink more bullish on Regenxbio, upgrades to Outperform Mar 06 8:03am ET Regenxbio upgraded to Outperform from Market Perform at Leerink Mar 06 6:57am ET Regenxbio price target raised to $39 from $34 at Baird Mar 05 2:55pm ET RegenXBio’s RGX-202 Hold Rating: Balancing Promising DMD Trial Outcomes with Competitive Market Challenges Mar 05 7:12am ET Regenxbio’s RGX-202 shows initial efficacy in Duchenne Mar 01 1:16am ET Optimistic Outlook for RegenXBio’s Gene Therapy Pipeline and Regulatory Prospects Spurs Buy Rating Mar 01 1:01am ET Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), uniQure (QURE) and RegenXBio (RGNX) Feb 28 7:18am ET RBC Capital Remains a Hold on RegenXBio (RGNX) Feb 28 6:56am ET RegenXBio: A Cautious Hold Amidst Gene Therapy Uncertainties and Pending Milestones Feb 28 3:36am ET RegenXBio (RGNX) was downgraded to a Buy Rating at Barclays Feb 27 4:08pm ET Regenxbio expects cash to fund operations into 2H25 Feb 27 4:06pm ET Regenxbio reports Q4 EPS ($1.34), consensus ($1.27) Feb 21 5:21am ET Regenxbio resumed with an Outperform at Raymond James Feb 12 6:45am ET Maintaining Hold on RegenXBio: A Cautious Stance Amidst Pipeline Uncertainties and Market Competition Feb 09 11:12am ET Biotech Alert: Searches spiking for these stocks today Feb 09 12:58am ET RegenXBio Buy Rating Backed by Strong Clinical Results and Strategic Regulatory Prospects Feb 09 12:50am ET RegenXBio’s Therapeutic Prospects: A Balanced Hold Rating Amid Clinical and Regulatory Uncertainties Feb 08 7:40am ET Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Verona Pharma (VRNA) and Molina Healthcare (MOH) Feb 08 5:20am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Molina Healthcare (MOH), Oscar Health (OSCR) and RegenXBio (RGNX) Feb 08 5:20am ET Buy Rating for RegenXBio Affirmed Amid Strong Clinical Prospects and Pipeline Momentum Feb 07 3:50pm ET Regenxbio to hold a conference call Feb 07 11:43am ET Regenxbio says CAMPSIITE trial of RGX-121 achieves primary endpoint

No recent press releases are available for RGNX

RGNX Financials

1-year income & revenue

Key terms

RGNX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

RGNX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms